Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
ApexOnco Front Page
Recent articles
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
Petosemtamab and ficerafusp alfa are among the biologicals to be featured at ASCO.
The company's refusal to run a randomised pivotal study of UGN-102 leads to an adcom thumbs down.
A pivotal trial of the group’s mutant-selective PI3Kα inhibitor, RLY-2608, will start in July.
An FDA adcom votes in favour of expansion into a multiple myeloma precursor.
Starglo isn't applicable to a US population, an adcom rules.
The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.
